Showing results (191-200 of 254) with videos related to
Sort By:
Pageof 26
Journal of Drugs in Dermatology : JDD|September 20, 2005
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyadsHelen Torok, Susan Taylor, Leslie Baumann, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.Clinical Pediatrics|February 13, 2010
Barriers to pediatric lead screening: implications from a web-based survey of Vermont pediatriciansBritton Keeshan, Catherine Avener, Amanda Abramson, et al.Cutis|October 2, 2002
Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeksJonathan Weiss, Alan Menter, Oscar Hevia, et al.Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.JAMA Dermatology|August 25, 2016
Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 DiabetesBobbak Mansouri, Dario Kivelevitch, Balaji Natarajan, et al.Journal of Medical Economics|June 5, 2019
Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI)Louis S Matza, John E Brazier, Katie D Stewart, et al.The New England Journal of Medicine|March 30, 2012
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasisKim A Papp, Craig Leonardi, Alan Menter, et al.Pageof 26